-3.1 C
New York
Tuesday, December 16, 2025

Sanofi’s Tolebrutinib does not meet primary endpoint in multiple sclerosis trial


Sanofi’s tolebrutinib fails primary endpoint in multiple sclerosis trial

Related Articles

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe

Latest Articles